VisionQuest i-Rx is a spinoff company of VisionQuest Biomedical, which was founded in 2007 to develop advanced medical imaging tools to improve the early detection and diagnosis of chronic diseases, especially those related to diabetes. VisionQuest i-Rx is an early stage business with a proven record of technical achievements. Inspired by the World Health Organization’s VISION 2020 initiative to eliminate avoidable blindness by 2020, the company’s emphasis is ophthalmology, targeting diabetic retinopathy and other diseases detectable in retinal images.

VisionQuest i-Rx’s flagship and patented EYESTAR™ automated reading system includes screening software product for evaluating retinal images acquired by existing and emerging retinal cameras. The EYESTAR™ software offers an economical alternative to current high-cost screening approaches through its real-time image quality assessment and automated reading software. When integrated with today’s low-cost retinal cameras, automatic reading is compatible with the needs of primary care clinics and other points-of-care facilities.


Our Mission

Periodic retinal screening can prevent vision loss in diabetic patients and others at risk for eye disease. We provide a convenient and economic means for meeting retinal screening recommendations, achieving preventive healthcare goals and most important of all, saving vision.

Our Vision

Make retinal screening accessible and affordable to every person at risk for diabetes-related blindness. We optimize science and technology to improve people’s lives. Our screening technology adds value to preventive care as mandated by the Affordable Care Act.

Our Values

We are committed to delivering the latest retinal screening technology to our clients and their patients. We work to provide exceptional service in our relationships with strategic partners, physicians, payors, and patients. We strive to make a difference through value-driven innovation that is accessible and affordable.